Users of drug giants’ Bayer and Johnson & Johnson billion-dollar blood thinner, Xarelto, have begun filing suit, claiming the drug led to severe internal bleeding, which sent them to the hospital.
The blood thinner is widely prescribed to aid in the prevention of strike and blood clots in patients who suffer from arterial fibrillation or who have recently undergone a hip or knee replacement surgery.
The FDA approved the blood thinner known as Xarelto (rivaroxaban) in 2011. Since it’s approval, the drug has been linked to hundreds of bleeding injuries and deaths.
Xarelto is a blood-thinning (anticoagulant) drug prescribed to treat a variety of heart problems, including blood clots, deep vein thrombosis, and pulmonary embolisms.
Part of its appeal, Xarelto is one of two blood-thinning drugs offered as an alternative to the well-prescribed blood thinner warfarin, which requires frequent dosage adjustments and certain limitations like dietary restrictions.
Xarelto Use Leads to Internal Bleeding
Unlike warfarin, a trusted anticoagulant used for decades, Xarelto has no antidote to stop uncontrollable bleeding, which can be fatal.
If a patient treated with Xarelto experiences a traumatic event, even a minor one, there’s no way to prevent uncontrollable bleeding due to Xarelto’s blood-thinning agent. Even if a patient makes it to the ER on time, there’s no guarantee that physicians will be able to stop the patient from bleeding out.
Studies have linked Xarelto to exposing patients to a higher risk of bleeding for acutely ill patients. The lawsuits claim Xarelto’s manufacturers downplayed the risks of bleeding and blood clots with use of Xarelto.
Help with Xarelto Lawsuits
Unfortunately, the drug makers of Xarelto continue to fail to warn of the dangerous and even deadly risks of Xarelto. Unlike Xarelto, older drugs like warfarin are reversible with vitamin A—making them much safer for patients who suffer from bleeding events.
The lawyers at Jones Ward PLC are evaluating Xarelto cases. For more information, contact attorney A. Layne Stackhouse at email@example.com or 502-882-6000.